In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey
Makaleler > Tam Makale · 2022
Yazarlar: Figen Sarıgül Yıldırım, Ülkü Üser, Nagehan Didem Sarı, Behice Kurtaran, Yusuf Önlen, Ebubekir Şenateş, Alper Gündüz, Esra Zerdali, Hasan Karsen, Ayşe Batırel, Rıdvan Karaali, Rahmet Güner, Tansu YAMAZHAN, Şükran Köse, Nurettin Erben, Nevin İnce, İftihar Köksal, Nefise Çuvalcı Öztoprak, Gülşen Yörük, Süheyla Kömür, Tayibe Bal, Sibel Kaya, İlkay Bozkurt, Özgür Günal, İlknur Esen Yıldız, Dilara İnan, Şener Barut, Mustafa Namıduru, Selma Tosun, Kamuran Türker, Alper Şener, Kenan Hızel, Nurcan Baykam, Fazilet Duygu, Hürrem Bodur, Güray Can, Hanefi Cem Gül, Ayşe Sağmak Tartar, Güven Çelebi, Mahmut Sünnetçioğlu, Oğuz Karabay, Hayat Kumbasar Karaosmanoğlu, Fatma Sırmatel, Fehmi Tabak
Turkish Journal of Gastroenterology, Uluslararası, Wos, 2022, cilt 33, ss 971-978
Özet
BACKGROUND: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. METHODS: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. RESULTS: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). CONCLUSION: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis.